CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
Nilotinibdrug
Likely dose
Nilotinib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00756509
NCT00756509Phase 4Completed
CompareCT.gov

An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment

Novartis Pharmaceuticals·interventional·Posted Sep 22, 2008·Updated Jan 20, 2026

In Brief

A Phase 4 clinical trial evaluating Nilotinib for Gastrointestinal Stromal Tumors. Completed, enrolled 34 participants across 7 sites in 4 countries.

Detailed Summary

The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesFinland, France, Germany, Italy
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 22, 2008
Enrollment StartAug 29, 2008
Primary CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 16.3 yearsPosted 17.8 years ago

Interventions

Nilotinibdrug

800 mg/d orally